1
|
Crisan D, Schneider LA, Kastler S, Scharffetter-Kochanek K, Crisan M, Radu C, Strilciuc S. Anatomical distribution of melanoma and non-melanoma skin cancer according to auricular subunits and gender: A single-centre retrospective analysis. Indian J Dermatol Venereol Leprol 2024; 0:1-3. [PMID: 38594976 DOI: 10.25259/ijdvl_620_2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 11/06/2023] [Indexed: 04/11/2024]
Affiliation(s)
- Diana Crisan
- Clinic of Dermatology and Allergology, University Clinic Ulm, Germany
| | | | - Sabine Kastler
- Clinic of Dermatology and Allergology, University Clinic Ulm, Germany
| | | | - Maria Crisan
- Department of Histology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
| | | | - Stefan Strilciuc
- Department of Neuroscience, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
| |
Collapse
|
2
|
Paun AGE, Chifor R, Radu C, Strilciuc Ş, Badea IC, Borzan CM. Oral health, the patients' perspective during the COVID 19 pandemic. Med Pharm Rep 2023; 96:305-309. [PMID: 37577022 PMCID: PMC10419691 DOI: 10.15386/mpr-2553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 08/19/2022] [Accepted: 08/31/2022] [Indexed: 08/15/2023] Open
Abstract
Background and aims On March 16, 2020, the state of emergency was established with drastic measures of isolation and quarantine. Among the measures taken in the context of the state of emergency was the closure of dental offices throughout the country. The aim of our questionnaire-based cross-sectional study was to identify the psycho-affective implications of the Romanian citizens induced by the COVID-19 pandemic period as well as their opinion related to the self-perceived oral health status during this period. Methods An original questionnaire was designed consisting of 41 questions, which were distributed to the general population via the Internet. The first part of the questionnaire investigated the respondents' opinion regarding the impact of this COVID-19 pandemic period of isolation on their oral health and the attention paid by the subjects to oral hygiene during restrictions. The second part refers to their addressability to the dental services during this pandemic and the third part interrogates different characteristics, namely the presence of comorbidities, possible anxiety, and stress. Results A total of 769 participants answered the questionnaire online. Conclusion According to their responses most of the respondents were not afraid of the possibility of contracting Sars-Cov-2 during dental treatments, but were in certain periods deprived of accessing dental services due to lockdown restrictions. They are aware of their oral health problems and pay more attention to oral hygiene so that they do not get worse during restrictions.
Collapse
Affiliation(s)
| | - Radu Chifor
- Department of Preventive Dental Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Constantin Radu
- RoNeuro, Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Ştefan Strilciuc
- Department of Neurosciences, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Iulia Clara Badea
- Department of Preventive Dental Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Cristina Maria Borzan
- Department of Public Health and Management, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| |
Collapse
|
3
|
Verisezan Rosu O, Jemna N, Hapca E, Benedek I, Vadan I, Muresanu I, Chira D, Radu C, Cherecheş R, Strilciuc S, Muresanu D. Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial. Front Neurosci 2023; 17:1186751. [PMID: 37360156 PMCID: PMC10285097 DOI: 10.3389/fnins.2023.1186751] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 05/22/2023] [Indexed: 06/28/2023] Open
Abstract
Introduction Traumatic brain injury (TBI) is a major public health problem affecting millions worldwide. Despite significant advances in medical care, there are limited effective interventions for improving cognitive and functional outcomes in TBI patients. Methods This randomized controlled trial investigated the safety and efficacy of combining repetitive transcranial magnetic stimulation (rTMS) and Cerebrolysin in improving cognitive and functional outcomes in TBI patients. Ninety-three patients with TBI were randomized to receive either Cerebrolysin and rTMS (CRB + rTMS), Cerebrolysin and sham stimulation (CRB + SHM), or placebo and sham stimulation (PLC + SHM). The primary outcome measures were the composite cognitive outcome scores at 3 and 6 months after TBI. Safety and tolerability were also assessed. Results The study results demonstrated that the combined intervention of rTMS and Cerebrolysin was safe and well-tolerated by patients with TBI. Although no statistically significant differences were observed in the primary outcome measures, the descriptive trends in the study support existing literature on the efficacy and safety of rTMS and Cerebrolysin. Discussion The findings of this study suggest that rTMS and Cerebrolysin may be effective interventions for improving cognitive and functional outcomes in TBI patients. However, limitations of the study, such as the small sample size and exclusion of specific patient populations, should be considered when interpreting the results. This study provides preliminary evidence for the safety and potential efficacy of combining rTMS and Cerebrolysin in improving cognitive and functional outcomes in TBI patients. The study highlights the importance of multidisciplinary approaches in TBI rehabilitation and the potential for combining neuropsychological measurements and interventions to optimize patient outcomes. Conclusion Further research is needed to establish these findings' generalizability and identify the optimal dosages and treatment protocols for rTMS and Cerebrolysin.
Collapse
Affiliation(s)
- Olivia Verisezan Rosu
- Department of Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Nicoleta Jemna
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Elian Hapca
- Department of Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Irina Benedek
- Department of Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Iulia Vadan
- Department of Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Ioana Muresanu
- Department of Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Diana Chira
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Constantin Radu
- Yale School of Public Health, Yale University, New Haven, CT, United States
| | - Răzvan Cherecheş
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
- Department of Public Health, Babeş-Bolyai University, Cluj-Napoca, Romania
| | - Stefan Strilciuc
- Department of Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Dafin Muresanu
- Department of Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| |
Collapse
|
4
|
Strilciuc S, Radu C, Grad DA, Stan AD, Vladescu C, Buzoianu AD, Muresanu D. Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study. Healthcare (Basel) 2023; 11:healthcare11101497. [PMID: 37239783 DOI: 10.3390/healthcare11101497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 05/08/2023] [Accepted: 05/18/2023] [Indexed: 05/28/2023] Open
Abstract
The cost-effectiveness of Cerebrolysin as an add-on therapy for moderate-severe acute ischemic stroke is a topic that remains understudied. This study aims to address this gap by performing a comprehensive cost-utility analysis using both deterministic and probabilistic methods from a payer perspective and within the Romanian inpatient care setting. Quality-adjusted life years (QALYs) were calculated using partial individual patient data from the 2016 Cerebrolysin and Recovery After Stroke (CARS) trial, utilizing three different health state valuation models. Cost data was extracted from actual acute care costs reported by Romanian public hospitals for reimbursement purposes for patients included in the CARS study. Incremental cost-effectiveness ratios were calculated for each treatment arm for the duration of the clinical trial. Deterministic analysis based on sample mean values indicates Cerebrolysin would be cost-effective at a threshold between roughly 18.8 and 29.9 thousand EUR, depending on valuation techniques. Probabilistic sensitivity analysis results indicate an 80% chance probability of cost-effectiveness of Cerebrolysin as an add-on therapy for acute ischemic stroke, considering a willingness-to-pay threshold of 50,000 EUR in a 90-day timeframe after stroke. Further economic evaluations of Cerebrolysin are needed to strengthen these findings, covering a timeframe of at least 12 months after the acute incident, which would account for treatment effects spanning beyond the first 90 days after ischemic stroke. These should be conducted to determine its cost-effectiveness under various care settings and patient pathways. Most importantly, modelling techniques are needed to answer important questions such as the estimates of population gain in QALYs after acute administration of Cerebrolysin and the potential offsetting of direct medical costs as a result of administering the intervention.
Collapse
Affiliation(s)
- Stefan Strilciuc
- Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania
- Department of Public Health, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, 400084 Cluj-Napoca, Romania
| | - Constantin Radu
- Yale School of Public Health, Yale University, New Haven, CT 06520, USA
| | - Diana-Alecsandra Grad
- RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania
- Department of Public Health, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, 400084 Cluj-Napoca, Romania
| | - Adina Dora Stan
- Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania
| | - Cristian Vladescu
- National Institute for Management of Health Services, 021254 București, Romania
- Faculty of Medicine, Titu Maiorescu University, 031595 București, Romania
| | - Anca Dana Buzoianu
- Department of Clinical Pharmacology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
| | - Dafin Muresanu
- Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania
| |
Collapse
|
5
|
Amza CG, Zapciu A, Baciu F, Radu C. Effect of UV-C Radiation on 3D Printed ABS-PC Polymers. Polymers (Basel) 2023; 15:polym15081966. [PMID: 37112113 PMCID: PMC10141134 DOI: 10.3390/polym15081966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/13/2023] [Accepted: 04/19/2023] [Indexed: 04/29/2023] Open
Abstract
During the initial stages of the COVID-19 pandemic, healthcare facilities experienced severe shortages of personal protective equipment (PPE) and other medical supplies. Employing 3D printing to rapidly fabricate functional parts and equipment was one of the emergency solutions used to tackle these shortages. Using ultraviolet light in the UV-C band (wavelengths of 200 nm to 280 nm) might prove useful in sterilizing 3D printed parts, enabling their reusability. Most polymers, however, degrade under UV-C radiation, so it becomes necessary to determine what 3D printing materials can withstand the conditions found during medical equipment sterilization with UV-C. This paper analyzes the effect of accelerated aging through prolonged exposure to UV-C on the mechanical properties of parts 3D printed from a polycarbonate and acrylonitrile butadiene styrene polymer (ABS-PC). Samples 3D printed using a material extrusion process (MEX) went through a 24-h UV-C exposure aging cycle and then were tested versus a control group for changes in tensile strength, compressive strength and some selected material creep characteristics. Testing showed minimal mechanical property degradation following the irradiation procedure, with tensile strength being statistically the same for irradiated parts as those in the control group. Irradiated parts showed small losses in stiffness (5.2%) and compressive strength (6.5%). Scanning electron microscopy (SEM) was employed in order to assess if any changes occurred in the material structure.
Collapse
Affiliation(s)
- Catalin Gheorghe Amza
- Faculty of Industrial Engineering and Robotics, University Politehnica of Bucharest, 060042 Bucharest, Romania
| | - Aurelian Zapciu
- Faculty of Industrial Engineering and Robotics, University Politehnica of Bucharest, 060042 Bucharest, Romania
| | - Florin Baciu
- Faculty of Industrial Engineering and Robotics, University Politehnica of Bucharest, 060042 Bucharest, Romania
| | - Constantin Radu
- Faculty of Industrial Engineering and Robotics, University Politehnica of Bucharest, 060042 Bucharest, Romania
| |
Collapse
|
6
|
Castellani C, Morillas Becerril L, Luisetto R, Radu C, Barison I, Fedrigo M, Giarraputo A, Virzì G, Tomaz Do Nascimento M, Simioni P, Papini E, Tavano R, Vescovo G, Mancin F, Angelini A. Optimization and Safety of Lipoic Acid F127@pla Nanoparticles as New Therapeutic Vector for Rna Delivery in Cardiovascular Diseases. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
7
|
Shum D, Bhinder B, Mahida J, Radu C, Calder PA, Djaballah H. A Genome-Wide RNAi Screen Reveals Common Host-Virus Gene Signatures: Implication for Dengue Antiviral Drug Discovery. GEN Biotechnol 2023; 2:133-148. [PMID: 37928776 PMCID: PMC10623629 DOI: 10.1089/genbio.2023.0001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Accepted: 04/02/2023] [Indexed: 11/07/2023]
Abstract
Dengue is the most common mosquito-borne viral disease that in recent years has become a major international public health concern. Dengue is a tropical neglected disease with increasing global incidences, affecting millions of people worldwide, and without the availability of specific treatments to combat it. The identification of host-target genes essential for the virus life cycle, for which effective modulators may already exist, would provide an alternative path to a rapid drug development of the much needed antidengue agents. For this purpose, we performed the first genome-wide RNAi screen, combining two high-content readouts for dengue virus infection (DENV E infection intensity) and host cell toxicity (host cell stained nuclei), against an arrayed lentiviral-based short hairpin RNA library covering 16,000 genes with a redundancy of at least 5 hairpins per gene. The screen identified 1924 gene candidates in total; of which, 1730 gene candidates abrogated dengue infection, whereas 194 gene candidates were found to enhance its infectivity in HEK293 cells. A first pass clustering analysis of hits revealed a well-orchestrated gene-network dependency on host cell homeostasis and physiology triggering distinct cellular pathways for infectivity, replication, trafficking, and egress; a second analysis revealed a comprehensive gene signature of 331 genes common to hits identified in 28 published RNAi host-viral interaction screens. Taken together, our findings provide novel antiviral molecular targets with the potential for drug discovery and development.
Collapse
Affiliation(s)
- David Shum
- HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Bhavneet Bhinder
- HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jeni Mahida
- HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Constantin Radu
- HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Paul A. Calder
- HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Hakim Djaballah
- HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Memorial Sloan Kettering Cancer Center, New York, New York, USA
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|
8
|
Mosca I, Radu C, Strilciuc Ș, Ungureanu MI. A five-year (2017-2021) time series evaluation of patient-reported informal healthcare payments in Romania. J Med Life 2023; 16:387-393. [PMID: 37168305 PMCID: PMC10165521 DOI: 10.25122/jml-2023-0080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2023] [Accepted: 03/02/2023] [Indexed: 05/13/2023] Open
Abstract
Low wages of health professionals are widely recognized as one of the drivers of informal payments in Romania's healthcare system. In January 2018, the government increased wages by an average of 70% to 172% in the public healthcare sector. This study examined the trends in patient-reported informal healthcare payments, discussing the effect of a one-time wage increase in 2018 and the impact of the COVID-19 pandemic in 2020 and 2021. It draws on monthly survey data of patient-reported informal payments collected between January 2017 and December 2021. We analyzed three periods: before the wage rise ("low pay"), between the wage rise and the COVID-19 pandemic ("high pay"), and during the COVID-19 pandemic. We found that patient-reported informal payments decreased between the "low pay" and "high pay" period but with a sharper decline during the COVID-19 pandemic. The share of respondents willing to report informal payments increased during the "high pay" period, indicating a stronger willingness to voice dissatisfaction with health services and informal payments, but slowed down during the first lockdown in 2020. Informal payments were more frequently reported in larger hospitals and the poorest geographical areas. While the 2018 wage increase may have contributed to less prevalent informal payments, survey coverage and design must be improved to draw robust, system-level conclusions to inform tailored policy actions.
Collapse
Affiliation(s)
| | - Constantin Radu
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
- Corresponding Author: Constantin Radu, RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania. E-mail:
| | - Ștefan Strilciuc
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
- Department of Neuroscience, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- Department of Public Health, Faculty of Political, Administrative, and Communication Sciences, Babeș-Bolyai University, Cluj-Napoca, Romania
| | - Marius-Ionuț Ungureanu
- Department of Public Health, Faculty of Political, Administrative, and Communication Sciences, Babeș-Bolyai University, Cluj-Napoca, Romania
- Center for Health Workforce Research and Policy, Faculty of Political, Administrative, and Communication Sciences, Babeș-Bolyai University, Cluj-Napoca, Romania
| |
Collapse
|
9
|
Tawaraishi T, Ochida A, Akao Y, Itono S, Kamaura M, Akther T, Shimada M, Canan S, Chowdhury S, Cao Y, Condroski K, Engkvist O, Francisco A, Ghosh S, Kaki R, Kelly JM, Kimura C, Kogej T, Nagaoka K, Naito A, Pairaudeau G, Radu C, Roberts I, Shum D, Watanabe NA, Xie H, Yonezawa S, Yoshida O, Yoshida R, Mowbray C, Perry B. Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection. J Med Chem 2023; 66:1221-1238. [PMID: 36607408 PMCID: PMC9884087 DOI: 10.1021/acs.jmedchem.2c00775] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Probing multiple proprietary pharmaceutical libraries in parallel via virtual screening allowed rapid expansion of the structure-activity relationship (SAR) around hit compounds with moderate efficacy against Trypanosoma cruzi, the causative agent of Chagas Disease. A potency-improving scaffold hop, followed by elaboration of the SAR via design guided by the output of the phenotypic virtual screening efforts, identified two promising hit compounds 54 and 85, which were profiled further in pharmacokinetic studies and in an in vivo model of T. cruzi infection. Compound 85 demonstrated clear reduction of parasitemia in the in vivo setting, confirming the interest in this series of 2-(pyridin-2-yl)quinazolines as potential anti-trypanosome treatments.
Collapse
Affiliation(s)
- Taisuke Tawaraishi
- Takeda
Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan
| | - Atsuko Ochida
- Takeda
Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yuichiro Akao
- Takeda
Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan
| | - Sachiko Itono
- Takeda
Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masahiro Kamaura
- Takeda
Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan
| | - Thamina Akther
- Takeda
Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan
| | - Mitsuyuki Shimada
- Takeda
Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan
| | - Stacie Canan
- Celgene
Corporation, Celgene Global Health, 10300 Campus Point Drive, San Diego, California 92121, United States
| | - Sanjoy Chowdhury
- TCG
Lifesciences, Plot No-7,
Salt Lake Electronics Complex, BN Block, Sector V, Kolkata 700091, India
| | - Yafeng Cao
- WuXi
AppTec Company Ltd., 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People’s Republic of China
| | - Kevin Condroski
- Celgene
Corporation, Celgene Global Health, 10300 Campus Point Drive, San Diego, California 92121, United States
| | - Ola Engkvist
- AstraZeneca
Discovery Sciences, R&D, Pepparedsleden 1, 431 50 Mölndal, Sweden
| | - Amanda Francisco
- London School
of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K.
| | - Sunil Ghosh
- TCG
Lifesciences, Plot No-7,
Salt Lake Electronics Complex, BN Block, Sector V, Kolkata 700091, India
| | - Rina Kaki
- Shionogi
& Co., Ltd, 3-1-1,
Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - John M. Kelly
- London School
of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K.
| | - Chiaki Kimura
- Shionogi
& Co., Ltd, 3-1-1,
Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Thierry Kogej
- AstraZeneca
Discovery Sciences, R&D, Pepparedsleden 1, 431 50 Mölndal, Sweden
| | - Kazuya Nagaoka
- Eisai
Co., Ltd, 1-3, Tokodai
5-chome, Tsukuba, Ibaraki 300-2635, Japan
| | - Akira Naito
- Shionogi
& Co., Ltd, 3-1-1,
Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Garry Pairaudeau
- AstraZeneca,
Discovery Sciences, R&D, The Darwin Building, 310 Milton Road, Milton, Cambridge CB4 0WG, U.K.
| | - Constantin Radu
- Institut
Pasteur Korea, 16, Daewangpangyo-ro
712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea
| | - Ieuan Roberts
- AstraZeneca,
Discovery Sciences, R&D, The Darwin Building, 310 Milton Road, Milton, Cambridge CB4 0WG, U.K.
| | - David Shum
- Institut
Pasteur Korea, 16, Daewangpangyo-ro
712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea
| | - Nao-aki Watanabe
- Eisai
Co., Ltd, 1-3, Tokodai
5-chome, Tsukuba, Ibaraki 300-2635, Japan
| | - Huanxu Xie
- WuXi
AppTec Company Ltd., 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People’s Republic of China
| | - Shuji Yonezawa
- Shionogi
& Co., Ltd, 3-1-1,
Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Osamu Yoshida
- Shionogi
& Co., Ltd, 3-1-1,
Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Ryu Yoshida
- Shionogi
& Co., Ltd, 3-1-1,
Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Charles Mowbray
- Drugs for Neglected
Diseases Initiative, 15 Chemin Camille Vidart, Geneva 1202, Switzerland
| | - Benjamin Perry
- Drugs for Neglected
Diseases Initiative, 15 Chemin Camille Vidart, Geneva 1202, Switzerland,
| |
Collapse
|
10
|
Benítez D, Franco J, Sardi F, Leyva A, Durán R, Choi G, Yang G, Kim T, Kim N, Heo J, Kim K, Lee H, Choi I, Radu C, Shum D, No JH, Comini MA. Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening. J Enzyme Inhib Med Chem 2022; 37:912-929. [PMID: 35306933 PMCID: PMC8942522 DOI: 10.1080/14756366.2022.2045590] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Trypanothione synthetase (TryS) catalyses the synthesis of N1,N8-bis(glutathionyl)spermidine (trypanothione), which is the main low molecular mass thiol supporting several redox functions in trypanosomatids. TryS attracts attention as molecular target for drug development against pathogens causing severe and fatal diseases in mammals. A drug discovery campaign aimed to identify and characterise new inhibitors of TryS with promising biological activity was conducted. A large compound library (n = 51,624), most of them bearing drug-like properties, was primarily screened against TryS from Trypanosoma brucei (TbTryS). With a true-hit rate of 0.056%, several of the TbTryS hits (IC50 from 1.2 to 36 µM) also targeted the homologue enzyme from Leishmania infantum and Trypanosoma cruzi (IC50 values from 2.6 to 40 µM). Calmidazolium chloride and Ebselen stand out for their multi-species anti-TryS activity at low µM concentrations (IC50 from 2.6 to 13.8 µM). The moieties carboxy piperidine amide and amide methyl thiazole phenyl were identified as novel TbTryS inhibitor scaffolds. Several of the TryS hits presented one-digit µM EC50 against T. cruzi and L. donovani amastigotes but proved cytotoxic against the human osteosarcoma and macrophage host cells (selectivity index ≤ 3). In contrast, seven hits showed a significantly higher selectivity against T. b. brucei (selectivity index from 11 to 182). Non-invasive redox assays confirmed that Ebselen, a multi-TryS inhibitor, induces an intracellular oxidative milieu in bloodstream T. b. brucei. Kinetic and mass spectrometry analysis revealed that Ebselen is a slow-binding inhibitor that modifies irreversible a highly conserved cysteine residue from the TryS’s synthetase domain. The most potent TbTryS inhibitor (a singleton containing an adamantine moiety) exerted a non-covalent, non-competitive (with any of the substrates) inhibition of the enzyme. These data feed the drug discovery pipeline for trypanosomatids with novel and valuable information on chemical entities with drug potential.
Collapse
Affiliation(s)
- Diego Benítez
- Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - Jaime Franco
- Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - Florencia Sardi
- Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - Alejandro Leyva
- Analytical Biochemistry and Proteomics Unit, Institut Pasteur de Montevideo, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay
| | - Rosario Durán
- Analytical Biochemistry and Proteomics Unit, Institut Pasteur de Montevideo, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay
| | - Gahee Choi
- Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Gyongseon Yang
- Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Taehee Kim
- Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Namyoul Kim
- Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Jinyeong Heo
- Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Kideok Kim
- Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Honggun Lee
- Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Inhee Choi
- Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Constantin Radu
- Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - David Shum
- Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Joo Hwan No
- Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea
| | - Marcelo A Comini
- Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay
| |
Collapse
|
11
|
Muresanu D, Popescu B, Strilciuc S, Radu C, Tiu C. Academia steps up to strengthen health policymaking in Romania: a roadmap for tackling difficulties encountered by Ministry of Health specialty commissions. J Med Life 2022; 14:591-593. [PMID: 35027960 PMCID: PMC8742890 DOI: 10.25122/jml-2021-1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 10/26/2021] [Indexed: 11/17/2022] Open
Affiliation(s)
- Dafin Muresanu
- Romanian Neurology Specialty Commission, Ministry of Health, Bucharest, Romania.,Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.,RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Bogdan Popescu
- Romanian Neurology Specialty Commission, Ministry of Health, Bucharest, Romania.,Department of Neurology, Colentina Clinical Hospital, Bucharest, Romania.,Department of Clinical Neurosciences, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Stefan Strilciuc
- Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.,RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Constantin Radu
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Cristina Tiu
- Romanian Neurology Specialty Commission, Ministry of Health, Bucharest, Romania.,Department of Clinical Neurosciences, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Stroke Unit, Department of Neurology, University Emergency Hospital, Bucharest, Romania
| |
Collapse
|
12
|
Strilciuc S, Grad DA, Radu C, Chira D, Stan A, Ungureanu M, Gheorghe A, Muresanu FD. The economic burden of stroke: a systematic review of cost of illness studies. J Med Life 2021; 14:606-619. [PMID: 35027963 PMCID: PMC8742896 DOI: 10.25122/jml-2021-0361] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 09/23/2021] [Indexed: 01/02/2023] Open
Abstract
Stroke is one of the leading causes of morbidity and mortality worldwide. As the number of stroke cases is rising from one year to another, policymakers require data on the amount spent on stroke to enforce better financing policies for prevention, hospital care, outpatient rehabilitation services and social services. We aimed to systematically assess the economic burden of stroke at global level. Cost of stroke studies were retrieved from five databases. We retrieved the average cost per patient, where specified, or estimated it using a top-down approach. Resulting costs were grouped in two main categories: per patient per year and per patient lifetime. We extracted information from forty-six cost of illness studies. Per patient per year costs are larger in high income countries and in studies conducted from the payer perspective. The highest average per patient per year cost by country was reported in the United States ($59,900), followed by Sweden ($52,725) and Spain ($41,950). The highest per patient lifetime costs were reported in Australia ($232,100) for all identified definitions of stroke. Existing literature regarding the economic burden of stroke is concentrated in high-income settings, with very few studies conducted in South America and Africa. Published manuscripts on this topic highlight substantial methodological heterogeneity, rendering comparisons difficult or impossible, even within the same country or among studies with similar costing perspectives.
Collapse
Affiliation(s)
- Stefan Strilciuc
- Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
- Department of Public Health, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, Cluj-Napoca, Romania
| | - Diana Alecsandra Grad
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
- Department of Public Health, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, Cluj-Napoca, Romania
| | - Constantin Radu
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Diana Chira
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Adina Stan
- Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - Marius Ungureanu
- Department of Public Health, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, Cluj-Napoca, Romania
- Center for Health Workforce Research and Policy, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, Cluj-Napoca, Romania
| | - Adrian Gheorghe
- Department of Infectious Disease Epidemiology, Global Health and Development Group, Imperial College London, London, United Kingdom
| | - Fior-Dafin Muresanu
- Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| |
Collapse
|
13
|
Akao Y, Canan S, Cao Y, Condroski K, Engkvist O, Itono S, Kaki R, Kimura C, Kogej T, Nagaoka K, Naito A, Nakai H, Pairaudeau G, Radu C, Roberts I, Shimada M, Shum D, Watanabe NA, Xie H, Yonezawa S, Yoshida O, Yoshida R, Mowbray C, Perry B. Collaborative virtual screening to elaborate an imidazo[1,2- a]pyridine hit series for visceral leishmaniasis. RSC Med Chem 2021; 12:384-393. [PMID: 34041487 PMCID: PMC8130605 DOI: 10.1039/d0md00353k] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
An innovative pre-competitive virtual screening collaboration was engaged to validate and subsequently explore an imidazo[1,2-a]pyridine screening hit for visceral leishmaniasis. In silico probing of five proprietary pharmaceutical company libraries enabled rapid expansion of the hit chemotype, alleviating initial concerns about the core chemical structure while simultaneously improving antiparasitic activity and selectivity index relative to the background cell line. Subsequent hit optimization informed by the structure–activity relationship enabled by this virtual screening allowed thorough investigation of the pharmacophore, opening avenues for further improvement and optimization of the chemical series. Ligand-based similarity screening of proprietary pharmaceutical company libraries enables rapid hit to lead investigation of a chemotype with anti-leishmania activity.![]()
Collapse
Affiliation(s)
- Yuichiro Akao
- Takeda Pharmaceutical Company Limited 26-1 Muraoka-Higashi 2-chrome Fujisawa Kanagawa 251-8555 Japan
| | - Stacie Canan
- Celgene Corporation, Celgene Global Health 10300 Campus Point Drive San Diego California 92121 USA
| | - Yafeng Cao
- WuXi AppTec Company Ltd. 666 Gaoxin Road, East Lake High-Tech Development Zone Wuhan 430075 People's Republic of China
| | - Kevin Condroski
- Celgene Corporation, Celgene Global Health 10300 Campus Point Drive San Diego California 92121 USA
| | - Ola Engkvist
- AstraZeneca Discovery Sciences, R&D AstraZeneca Gothenburg Sweden
| | - Sachiko Itono
- Takeda Pharmaceutical Company Limited 26-1 Muraoka-Higashi 2-chrome Fujisawa Kanagawa 251-8555 Japan
| | - Rina Kaki
- Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan
| | - Chiaki Kimura
- Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan
| | - Thierry Kogej
- AstraZeneca Discovery Sciences, R&D AstraZeneca Gothenburg Sweden
| | - Kazuya Nagaoka
- Eisai Co., Ltd 1-3,Tokodai 5-chome Tsukuba Ibaraki 300-2635 Japan
| | - Akira Naito
- Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan
| | - Hiromi Nakai
- Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan
| | | | - Constantin Radu
- Institut Pasteur Korea 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu Seongnam-si Gyeonggi-do 13488 Republic of Korea
| | - Ieuan Roberts
- AstraZeneca, Discovery Sciences, R&D AstraZeneca Cambridge UK
| | - Mitsuyuki Shimada
- Takeda Pharmaceutical Company Limited 26-1 Muraoka-Higashi 2-chrome Fujisawa Kanagawa 251-8555 Japan
| | - David Shum
- Institut Pasteur Korea 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu Seongnam-si Gyeonggi-do 13488 Republic of Korea
| | - Nao-Aki Watanabe
- Eisai Co., Ltd 1-3,Tokodai 5-chome Tsukuba Ibaraki 300-2635 Japan
| | - Huanxu Xie
- WuXi AppTec Company Ltd. 666 Gaoxin Road, East Lake High-Tech Development Zone Wuhan 430075 People's Republic of China
| | - Shuji Yonezawa
- Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan
| | - Osamu Yoshida
- Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan
| | - Ryu Yoshida
- Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan
| | - Charles Mowbray
- Drugs for Neglected Diseases initiative 15 Chemin Louis Dunant Geneva 1202 Switzerland
| | - Benjamin Perry
- Drugs for Neglected Diseases initiative 15 Chemin Louis Dunant Geneva 1202 Switzerland
| |
Collapse
|
14
|
Mezdari Z, Pini M, Czibik G, Ternacle J, Riant E, Radu C, Zhang Y, Clerc F, Adnot S, Derumeaux G, Sawaki D. Role of adipose tissue macrophages in the cross-talk between visceral adipose tissue and heart during high fat diet. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Wemmert C, Fourreau F, Radu C, Balan A, Gomart C, Fiore A, La Martire G, Decousser J, Lepeule R. Traitement médical des sternites post sternotomie : 21 jours suffisent ? Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Crisan D, Grigorescu M, Crisan N, Craciun R, Lupsor M, Radu C, Grigorescu MD, Suciu A, Epure F, Avram L, Leach N. Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters. J Physiol Pharmacol 2019; 70. [PMID: 31642820 DOI: 10.26402/jpp.2019.4.09] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 08/28/2019] [Indexed: 11/03/2022]
Abstract
There is an established correlation between the PNPLA3 rs738409 C > G single nucleotide polymorphism (SNP) and hepatic steatosis and fibrosis in hepatitis C virus (HCV) infected patients. However not all data is convergent regarding the exact impact of this SNP on the pattern of disease progression in different clinical settings. In this study, we aimed to further bridge the knowledge gap on this topic by investigating the role of the G allele in promoting steatosis, fibrosis and disease progression in relation to other metabolic and anthropometric host factors. Two hundred and fifty consecutive patients, previously diagnosed with chronic hepatitis C (CHC) underwent liver biopsy. Histology was assessed using the Metavir scoring system. Transient elastography was used for follow-up. Ninety-eight patients were genotyped for PNPLA3 rs738409 and followed up for fibrosis progression. PNPLA3 rs738409[G] allele was significantly correlated with severe steatosis (P = 0.04), severe fibrosis at the time of enrollment (P = 0.0005) and fibrosis progression with an OR of 10.31 (95% CI 1.06 - 99.59, P = 0.04), after a mean follow-up time of 62.85 (95%CI: 52.21 - 76.15) months. Severe steatosis at the time of enrollment had an OR of 11.02 (95% CI 1.48 - 82.09, P = 0.01) for the association with fibrosis progression. The HOMA-IR index was also positively correlated with severe fibrosis (P = 0.03) and fibrosis progression on univariate analysis (P = 0.02). PNPLA3 rs738409[G] allele is a reliable predictor for steatosis and fibrosis in CHC. The presence of G allele, along with severe steatosis and insulin resistance are significant predictors for fibrosis progression.
Collapse
Affiliation(s)
- D Crisan
- Fifth Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.,Municipal Clinical Hospital, Cluj-Napoca, Romania
| | - M Grigorescu
- Third Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.,"Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Romania
| | - N Crisan
- Municipal Clinical Hospital, Cluj-Napoca, Romania. .,Department of Surgical Specialties, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - R Craciun
- "Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Romania.
| | - M Lupsor
- "Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Romania.,Department of Medical Imaging, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - C Radu
- Third Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.,"Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Romania
| | - M D Grigorescu
- "Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Romania
| | - A Suciu
- "Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, Romania
| | - F Epure
- Department of Medical Imaging, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - L Avram
- Fifth Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.,Municipal Clinical Hospital, Cluj-Napoca, Romania
| | - N Leach
- Fourth Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| |
Collapse
|
17
|
Flores A, Sandoval-Gonzalez S, Takahashi R, Krall A, Sathe L, Wei L, Radu C, Joly JH, Graham NA, Christofk HR, Lowry WE. Author Correction: Increased lactate dehydrogenase activity is dispensable in squamous carcinoma cells of origin. Nat Commun 2019; 10:1449. [PMID: 30914644 PMCID: PMC6435690 DOI: 10.1038/s41467-019-09435-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- A Flores
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA.,Broad Center for Regenerative Medicine, UCLA, Los Angeles, 90095, CA, USA.,Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, 90089, CA, USA
| | - S Sandoval-Gonzalez
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA
| | - R Takahashi
- Division of Dermatology, David Geffen School of Medicine, UCLA, Los Angeles, 90095, CA, USA
| | - A Krall
- Department of Biological Chemistry, UCLA, Los Angeles, 90095, CA, USA
| | - L Sathe
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA
| | - L Wei
- Department of Pharmacology, UCLA, Los Angeles, 90095, CA, USA
| | - C Radu
- Department of Pharmacology, UCLA, Los Angeles, 90095, CA, USA
| | - J H Joly
- Department of Engineering, USC, Los Angeles, 90089, CA, USA.,Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, 90089, CA, USA
| | - N A Graham
- Department of Engineering, USC, Los Angeles, 90089, CA, USA.,Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, 90089, CA, USA.,Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, 90089, CA, USA
| | - H R Christofk
- Department of Biological Chemistry, UCLA, Los Angeles, 90095, CA, USA. .,Department of Pharmacology, UCLA, Los Angeles, 90095, CA, USA. .,Molecular Biology Institute, UCLA, Los Angeles, 90095, CA, USA. .,Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, 90095, CA, USA.
| | - W E Lowry
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA. .,Broad Center for Regenerative Medicine, UCLA, Los Angeles, 90095, CA, USA. .,Division of Dermatology, David Geffen School of Medicine, UCLA, Los Angeles, 90095, CA, USA. .,Molecular Biology Institute, UCLA, Los Angeles, 90095, CA, USA. .,Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, 90095, CA, USA.
| |
Collapse
|
18
|
Flores A, Sandoval-Gonzalez S, Takahashi R, Krall A, Sathe L, Wei L, Radu C, Joly JH, Graham NA, Christofk HR, Lowry WE. Increased lactate dehydrogenase activity is dispensable in squamous carcinoma cells of origin. Nat Commun 2019; 10:91. [PMID: 30626875 PMCID: PMC6327029 DOI: 10.1038/s41467-018-07857-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 12/04/2018] [Indexed: 12/17/2022] Open
Abstract
Although numerous therapeutic strategies have attempted to target aerobic glycolysis to inhibit tumor progression, these approaches have not resulted in effective clinical outcomes. Murine squamous cell carcinoma (SCC) can be initiated by hair follicle stem cells (HFSCs). HFSCs utilize aerobic glycolysis, and the activity of lactate dehydrogenase (Ldh) is essential for HFSC activation. We sought to determine whether Ldh activity in SCC is critical for tumorigenesis or simply a marker of the cell type of origin. Genetic abrogation or induction of Ldh activity in HFSC-mediated tumorigenesis shows no effect on tumorigenesis as measured by number, time to formation, proliferation, volume, epithelial to mesenchymal transition, gene expression, or immune response. Ldha-null tumors show dramatically reduced levels of glycolytic metabolites by metabolomics, and significantly reduced glucose uptake by FDG-PET live animal imaging. These results suggest that squamous cancer cells of origin do not require increased glycolytic activity to generate cancers. Most tumours are characterized by increased aerobic glycolytic activity. Here the authors show that elevated aerobic glycolysis is not essential for cancer initiation by testing the effect of lactate dehydrogenase depletion on the ability of hair follicle stem cells (HFSCs) to form squamous cell carcinoma (SCC) in mouse genetic models.
Collapse
Affiliation(s)
- A Flores
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA.,Broad Center for Regenerative Medicine, UCLA, Los Angeles, 90095, CA, USA.,Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, 90089, CA, USA
| | - S Sandoval-Gonzalez
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA
| | - R Takahashi
- Division of Dermatology, David Geffen School of Medicine, UCLA, Los Angeles, 90095, CA, USA
| | - A Krall
- Department of Biological Chemistry, UCLA, Los Angeles, 90095, CA, USA
| | - L Sathe
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA
| | - L Wei
- Department of Pharmacology, UCLA, Los Angeles, 90095, CA, USA
| | - C Radu
- Department of Pharmacology, UCLA, Los Angeles, 90095, CA, USA
| | - J H Joly
- Department of Engineering, USC, Los Angeles, 90089, CA, USA.,Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, 90089, CA, USA
| | - N A Graham
- Department of Engineering, USC, Los Angeles, 90089, CA, USA.,Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, 90089, CA, USA.,Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, 90089, CA, USA
| | - H R Christofk
- Department of Biological Chemistry, UCLA, Los Angeles, 90095, CA, USA. .,Department of Pharmacology, UCLA, Los Angeles, 90095, CA, USA. .,Molecular Biology Institute, UCLA, Los Angeles, 90095, CA, USA. .,Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, 90095, CA, USA.
| | - W E Lowry
- Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, 90095, CA, USA. .,Broad Center for Regenerative Medicine, UCLA, Los Angeles, 90095, CA, USA. .,Division of Dermatology, David Geffen School of Medicine, UCLA, Los Angeles, 90095, CA, USA. .,Molecular Biology Institute, UCLA, Los Angeles, 90095, CA, USA. .,Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, 90095, CA, USA.
| |
Collapse
|
19
|
Lee N, Shum D, König A, Kim H, Heo J, Min S, Lee J, Ko Y, Choi I, Lee H, Radu C, Hoenen T, Min JY, Windisch MP. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system. Antiviral Res 2018; 158:226-237. [DOI: 10.1016/j.antiviral.2018.08.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 08/16/2018] [Accepted: 08/20/2018] [Indexed: 12/24/2022]
|
20
|
Mezdari Z, Pini M, Czibik G, Ternacle J, Radu C, Zhang Y, Adnot S, Henegar C, Derumeaux GA, Sawaki D. P2536Role of adipose tissue macrophages in the cross-talk between visceral adipose tissue and heart during high fat diet. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2536] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Z Mezdari
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - M Pini
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - G Czibik
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - J Ternacle
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - C Radu
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - Y Zhang
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - S Adnot
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - C Henegar
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| | - G A Derumeaux
- Inserm U886, University Claude Bernard Lyon 1, Lyon, France
| | - D Sawaki
- University Hospital Henri Mondor, DHU ATVB, APHP, UPEC, Creteil, France
| |
Collapse
|
21
|
Affiliation(s)
- Inhee Choi
- Cheminformatics; Institut Pasteur Korea; Seongnam-si 13488 Republic of Korea
| | - Yoonae Ko
- Cheminformatics; Institut Pasteur Korea; Seongnam-si 13488 Republic of Korea
| | - Honggun Lee
- Automation & Logistics Management; Institut Pasteur Korea; Seongnam-si 13488 Republic of Korea
| | - Kideok Kim
- Automation & Logistics Management; Institut Pasteur Korea; Seongnam-si 13488 Republic of Korea
| | - Constantin Radu
- Automation & Logistics Management; Institut Pasteur Korea; Seongnam-si 13488 Republic of Korea
| |
Collapse
|
22
|
Khayath N, Radu C, Choual I, Jilani S, Vecellio L, Domis N, De Blay F. [Environmental exposure chambers (EEC): A novel tool for pathophysiological and pharmaceutical research]. Rev Mal Respir 2018; 35:390-402. [PMID: 29731373 DOI: 10.1016/j.rmr.2018.01.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 09/15/2017] [Indexed: 01/27/2023]
Abstract
Airborne allergic diseases (allergic asthma, rhinitis and conjunctivitis) have reached epidemic proportions and are a great burden for both society and individuals. Therefore we need to better understand the physiopathological mechanisms and to increase clinical research in these diseases. However, traditional outpatient studies are difficult and have number of limitations, in particular the variability of allergen exposure. Yet allergen provocation tests, especially bronchial challenges in asthma, are excellent tools to measure the efficiency of anti-allergic therapies. Environmental exposure chambers (EEC) allow the performance of controlled allergen provocation tests on a large scale with remarkable sensitivity, specificity and reproducibility. Moreover, they allow a precise collection of allergic symptoms, making them interesting tools for patho-physiological and clinical studies. During the last thirty years, they have assisted the study of anti-allergic therapies and provided data on their pharmacodynamic characteristics, particularly in allergic rhinitis. However, there are still no EEC tests centered on asthma. The EEC of Strasbourg (ALYATEC®) was developed to fulfill two objectives: to allow standardized allergenic and non-allergenic exposures with better control of the parameters than in other EEC and to offer a place to study asthma and anti-asthmatic therapies safely.
Collapse
Affiliation(s)
- N Khayath
- Service de pneumologie, pôle de pathologie thoracique, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France; Fédération de médecine translationnelle, université de Strasbourg, BP426, 67091 Strasbourg, France
| | - C Radu
- Service de pneumologie, pôle de pathologie thoracique, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France; Alyatec, Biocluster-des-Haras, 23, rue des Glacières, 67000 Strasbourg, France
| | - I Choual
- Alyatec, Biocluster-des-Haras, 23, rue des Glacières, 67000 Strasbourg, France
| | - S Jilani
- Alyatec, Biocluster-des-Haras, 23, rue des Glacières, 67000 Strasbourg, France
| | - L Vecellio
- Université François-Rabelais, 37020 Tours cedex, France
| | - N Domis
- Alyatec, Biocluster-des-Haras, 23, rue des Glacières, 67000 Strasbourg, France
| | - F De Blay
- Service de pneumologie, pôle de pathologie thoracique, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France; Fédération de médecine translationnelle, université de Strasbourg, BP426, 67091 Strasbourg, France.
| |
Collapse
|
23
|
Pini M, Czibik G, Sawaki D, Mercedes R, Ternacle J, Henegar C, Braud L, Mezdari Z, Radu C, Dubois-Randé J, Adnot S, Foresti R, Motterlini R, Derumeaux G. Exercise rescues obesity-induced adipose tissue premature aging and restores cardio-metabolic homeostasis. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
24
|
Fard D, D’humières T, Bergoend E, Radu C, Deux J, Benhaiem N, Oliver L, Brault-Meslin O, Couetil J, Dubois-Randé J, Lim P, Ternacle J. A new modality for assessing aortic calcium score by 3D trans-esophageal echocardiography. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
De Blay F, Radu C, Choual I, Khayath N, Jilani S, Beck N, Smet S, Domis N. Validation clinique de la chambre d’exposition environnementale de Strasbourg (ALYATEC ® ) chez des patients asthmatiques allergiques aux acariens. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Lee H, Radu C, Han JW, Grailhe R. Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells. J Vis Exp 2017. [PMID: 29053667 DOI: 10.3791/56425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that can be caused by inherited mutations in the gene encoding copper-zinc superoxide dismutase 1 (SOD1). The structural instability of SOD1 and the detection of SOD1-positive inclusions in familial-ALS patients supports a potential causal role for misfolded and/or aggregated SOD1 in ALS pathology. In this study, we describe the development of a cell-based assay designed to quantify the dynamics of SOD1 aggregation in living cells by high content screening approaches. Using lentiviral vectors, we generated stable cell lines expressing wild-type and mutant A4V SOD1 tagged with yellow fluorescent protein and found that both proteins were expressed in the cytosol without any sign of aggregation. Interestingly, only SOD1 A4V stably expressed in HEK-293, but not in U2OS or SH-SY5Y cell lines, formed aggregates upon proteasome inhibitor treatment. We show that it is possible to quantify aggregation based on dose-response analysis of various proteasome inhibitors, and to track aggregate-formation kinetics by time-lapse microscopy. Our approach introduces the possibility of quantifying the effect of ALS mutations on the role of SOD1 in aggregate formation as well as screening for small molecules that prevent SOD1 A4V aggregation.
Collapse
Affiliation(s)
- Honggun Lee
- Automation & Logistics Management, Screening Sciences & Novel Assay Technologies, Institut Pasteur Korea
| | - Constantin Radu
- Automation & Logistics Management, Screening Sciences & Novel Assay Technologies, Institut Pasteur Korea
| | | | - Regis Grailhe
- Technology Development Platform, Institut Pasteur Korea;
| |
Collapse
|
27
|
Damy T, Galat A, Rouffiac S, Guendouz S, Kharoubi M, Ayad K, De Nadai N, Plante-Bordeneuve V, Lebras F, Amiot A, Radu C, Dubois-Rande J, Bodez D. P5845Prognosis of patients with cardiac amyloidosis referred in the French cardiac amyloidosis expert center. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T. Damy
- AP-HP - University Hospital Henri Mondor, Creteil, France
| | - A. Galat
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | - S. Rouffiac
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | - S. Guendouz
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | - M. Kharoubi
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | - K. Ayad
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | - N. De Nadai
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | | | - F. Lebras
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | - A. Amiot
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | - C. Radu
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | | | - D. Bodez
- GRC-Amyloid Research Institute - APHP - INSERM, Creteil, France
| | | |
Collapse
|
28
|
Ibáñez G, Calder PA, Radu C, Bhinder B, Shum D, Antczak C, Djaballah H. Evaluation of Compound Optical Interference in High-Content Screening. SLAS Discov 2017; 23:321-329. [PMID: 28467117 DOI: 10.1177/2472555217707725] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Compound optical interference remains an inherent problem in chemical screening and has been well documented for biochemical assays and less so for automated microscopy-based assays. It has also been the assumption that the latter should not suffer from such interference because of the washing steps involved in the process, thus eliminating the residual nonspecific compound effects. Instead, these compounds may have no relevance to the actual target, and as such, compound optical interference contributes to a number of false-positives, resulting in a high attrition rate during subsequent follow-up studies. In this report, we analyze the outcome of a high-content screen using enhanced green fluorescent protein as a reporter in a gain-of-function cell-based assay in search of modulators of the micro RNA (miRNA) biogenesis pathway. Using a previously validated image-based biosensor, we screened a diverse library collection of ~315,000 compounds covering natural and synthetic derivatives in which 1130 positives were identified to enhance green fluorescence expression. Lateral confirmation and dose-response studies revealed that all of these compounds were the result of optical interference and not specific inhibition of miRNA biogenesis. Here, we highlight the chemical classes that are susceptible to compound optical interference and discuss their implications in automated microscopy-based assays.
Collapse
Affiliation(s)
- Glorymar Ibáñez
- 1 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.,2 HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Paul A Calder
- 1 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.,2 HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Constantin Radu
- 3 Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, Republic of Korea
| | - Bhavneet Bhinder
- 2 HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,4 Weill Cornell Medicine, New York, NY, USA
| | - David Shum
- 2 HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,3 Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, Republic of Korea
| | - Christophe Antczak
- 2 HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,5 Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Hakim Djaballah
- 2 HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,6 Keren Therapeutics, Scarsdale, NY, USA
| |
Collapse
|
29
|
Crisan D, Radu C, Suciu A, Leach N, Stefanescu H, Avram L, Crisan N, Grigorescu M. Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference. J Viral Hepat 2017; 24:86-87. [PMID: 27700001 DOI: 10.1111/jvh.12610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- D Crisan
- 5th Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.,Clinical Municipal Hospital, Cluj-Napoca, Romania
| | - C Radu
- 3rd Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.,Hepatology Unit, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
| | - A Suciu
- 3rd Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - N Leach
- 4th Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - H Stefanescu
- Hepatology Unit, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
| | - L Avram
- Clinical Municipal Hospital, Cluj-Napoca, Romania
| | - N Crisan
- Clinical Municipal Hospital, Cluj-Napoca, Romania.,Department of Surgery, Iuliu-Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - M Grigorescu
- Hepatology Unit, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
| |
Collapse
|
30
|
Heo J, Nam J, Jang J, Shum D, Radu C, Cheng J, Lee H, Suh JW, Delorme V. High-Content Screening of Raw Actinomycete Extracts for the Identification of Antituberculosis Activities. SLAS Discov 2016; 22:144-154. [PMID: 27810952 DOI: 10.1177/1087057116675887] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The feasibility and relevance of screening a library of raw actinomycete extracts (ECUM library) for the identification of antituberculosis activities was assessed on 11,088 extracts using a multiple-screening approach. Each extract was first tested at two concentrations against noninfected macrophages as a control, then against Mycobacterium tuberculosis growing in broth medium as well as infecting murine macrophages. The screening results indicated a library of good quality with an apparent low proportion of cytotoxic extracts. A correlation was found between both bacterial assays, but the intracellular assay showed limitations due to low rates of cell survival. Several extracts of interest were highlighted by this multiple screening. A focus on the strain producing the two most effective revealed similarities with known producers of active molecules, suggesting the possibility of selecting relevant extracts using this strategy.
Collapse
Affiliation(s)
- Jinyeong Heo
- 1 Institut Pasteur Korea, Assay Development & Screening, Seongnam, Gyeonggi, Republic of Korea
| | - Jiyoun Nam
- 1 Institut Pasteur Korea, Assay Development & Screening, Seongnam, Gyeonggi, Republic of Korea
| | - Jichan Jang
- 2 Molecular Mechanism of Antibiotics, Division of Life Science, Research Institute of Life Science, Gyeongsang National University, Jinju, Gyeongnam, Republic of Korea
| | - David Shum
- 1 Institut Pasteur Korea, Assay Development & Screening, Seongnam, Gyeonggi, Republic of Korea
| | - Constantin Radu
- 3 Institut Pasteur Korea, Automation & Logistics Management, Seongnam, Gyeonggi, Republic of Korea
| | - Jinhua Cheng
- 4 Division of Bioscience and Bioinformatics, College of Natural Science, Myongji University, Yongin, Gyeonggi, Republic of Korea.,5 Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin, Gyeonggi, Republic of Korea
| | - Hanki Lee
- 5 Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin, Gyeonggi, Republic of Korea.,6 Interdisciplinary Program of Biomodulation, Myongji University, Yongin, Gyeonggi, Republic of Korea
| | - Joo-Won Suh
- 4 Division of Bioscience and Bioinformatics, College of Natural Science, Myongji University, Yongin, Gyeonggi, Republic of Korea.,5 Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin, Gyeonggi, Republic of Korea
| | - Vincent Delorme
- 7 Institut Pasteur Korea, Tuberculosis Research Laboratory, Seongnam, Gyeonggi, Republic of Korea
| |
Collapse
|
31
|
Affiliation(s)
- C Radu
- Department of Chest Disease, University Hospital of Strasbourg, France
| | - C Barnig
- Department of Chest Disease, University Hospital of Strasbourg, France.,Federation of Translational Medicine, EA3072, University of Strasbourg, France
| | - F de Blay
- Department of Chest Disease, University Hospital of Strasbourg, France.,Federation of Translational Medicine, EA3072, University of Strasbourg, France
| |
Collapse
|
32
|
Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, D'Arcy P, Wang X, Kobos R, Antczak C, Bhinder B, Shum D, Radu C, Yang G, Taylor BS, Ng CKY, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M. Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer Res 2016; 76:4525-34. [PMID: 27256563 DOI: 10.1158/0008-5472.can-16-1040] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2016] [Accepted: 05/09/2016] [Indexed: 01/05/2023]
Abstract
Ewing sarcoma is a primitive round cell sarcoma with a peak incidence in adolescence that is driven by a chimeric oncogene created from the fusion of the EWSR1 gene with a member of the ETS family of genes. Patients with metastatic and recurrent disease have dismal outcomes and need better therapeutic options. We screened a library of 309,989 chemical compounds for growth inhibition of Ewing sarcoma cells to provide the basis for the development of novel therapies and to discover vulnerable pathways that might broaden our understanding of the pathobiology of this aggressive sarcoma. This screening campaign identified a class of benzyl-4-piperidone compounds that selectively inhibit the growth of Ewing sarcoma cell lines by inducing apoptosis. These agents disrupt 19S proteasome function through inhibition of the deubiquitinating enzymes USP14 and UCHL5. Functional genomic data from a genome-wide shRNA screen in Ewing sarcoma cells also identified the proteasome as a node of vulnerability in Ewing sarcoma cells, providing orthologous confirmation of the chemical screen findings. Furthermore, shRNA-mediated silencing of USP14 or UCHL5 in Ewing sarcoma cells produced significant growth inhibition. Finally, treatment of a xenograft mouse model of Ewing sarcoma with VLX1570, a benzyl-4-piperidone compound derivative currently in clinical trials for relapsed multiple myeloma, significantly inhibited in vivo tumor growth. Overall, our results offer a preclinical proof of concept for the use of 19S proteasome inhibitors as a novel therapeutic strategy for Ewing sarcoma. Cancer Res; 76(15); 4525-34. ©2016 AACR.
Collapse
Affiliation(s)
- Neerav Shukla
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
| | - Romel Somwar
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Roger S Smith
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sri Ambati
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Stanley Munoz
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Melinda Merchant
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Padraig D'Arcy
- Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
| | - Xin Wang
- Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
| | - Rachel Kobos
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Christophe Antczak
- High-Throughput Drug Screening Facility, Memorial Sloan Kettering Cancer Center, New YorkNew York
| | - Bhavneet Bhinder
- High-Throughput Drug Screening Facility, Memorial Sloan Kettering Cancer Center, New YorkNew York
| | - David Shum
- High-Throughput Drug Screening Facility, Memorial Sloan Kettering Cancer Center, New YorkNew York
| | - Constantin Radu
- High-Throughput Drug Screening Facility, Memorial Sloan Kettering Cancer Center, New YorkNew York
| | - Guangbin Yang
- Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Barry S Taylor
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Charlotte K Y Ng
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Britta Weigelt
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Inna Khodos
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Elisa de Stanchina
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jorge S Reis-Filho
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ouathek Ouerfelli
- Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Stig Linder
- Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden
| | - Hakim Djaballah
- High-Throughput Drug Screening Facility, Memorial Sloan Kettering Cancer Center, New YorkNew York
| | - Marc Ladanyi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
33
|
Kremer T, Cordts T, Hirche C, Hernekamp F, Radu C, Kneser U. [Reconstruction of Defects after Oncologic Resection and Radiation - Indications for Microsurgical Reconstruction]. HANDCHIR MIKROCHIR P 2015; 47:353-8. [PMID: 26676555 DOI: 10.1055/s-0041-108197] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
The surgical treatment of soft tissue sarcomas in the extremities frequently requires radiation therapy to achieve local tumour control. However, both adjuvant and neoadjuvant radiation are associated with significant morbidity caused by impaired wound healing, ulcers or osteonecrosis with subsequent fractures. This is due to altered local cell mediator levels, fibrosis occurring simultaneously with decreased cell division rates and diminished vascularity. This article describes a number of local conservative treatment options, all of which have limited success rates. In addition, it describes plastic surgical treatment options for radiation-induced local morbidity. Surgical reconstruction includes the full range of plastic reconstructive techniques. However, less complex options such as random pattern flaps or split thickness skin grafts are often associated with complications. Therefore, a large number of cases require free tissue transfer.
Collapse
Affiliation(s)
- T Kremer
- BG Unfallklinik Ludwigshafen und Ruprecht-Karls-Universität Heidelberg, Klinik für Hand, Plastische und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie, Ludwigshafen
| | - T Cordts
- BG Unfallklinik Ludwigshafen und Ruprecht-Karls-Universität Heidelberg, Klinik für Hand, Plastische und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie, Ludwigshafen
| | - C Hirche
- BG Unfallklinik Ludwigshafen und Ruprecht-Karls-Universität Heidelberg, Klinik für Hand, Plastische und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie, Ludwigshafen
| | - F Hernekamp
- BG Unfallklinik Ludwigshafen und Ruprecht-Karls-Universität Heidelberg, Klinik für Hand, Plastische und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie, Ludwigshafen
| | - C Radu
- BG Unfallklinik Ludwigshafen und Ruprecht-Karls-Universität Heidelberg, Klinik für Hand, Plastische und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie, Ludwigshafen
| | - U Kneser
- BG Unfallklinik Ludwigshafen und Ruprecht-Karls-Universität Heidelberg, Klinik für Hand, Plastische und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie, Ludwigshafen
| |
Collapse
|
34
|
Minuesa G, Antczak C, Shum D, Radu C, Bhinder B, Li Y, Djaballah H, Kharas MG. A 1536-well fluorescence polarization assay to screen for modulators of the MUSASHI family of RNA-binding proteins. Comb Chem High Throughput Screen 2015; 17:596-609. [PMID: 24912481 DOI: 10.2174/1386207317666140609122714] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Revised: 05/31/2014] [Accepted: 06/09/2014] [Indexed: 11/22/2022]
Abstract
RNA-binding proteins (RBPs) can act as stem cell modulators and oncogenic drivers, but have been largely ignored by the pharmaceutical industry as potential therapeutic targets for cancer. The MUSASHI (MSI) family has recently been demonstrated to be an attractive clinical target in the most aggressive cancers. Therefore, the discovery and development of small molecule inhibitors could provide a novel therapeutic strategy. In order to find novel compounds with MSI RNA binding inhibitory activity, we have developed a fluorescence polarization (FP) assay and optimized it for high throughput screening (HTS) in a 1536-well microtiter plate format. Using a chemical library of 6,208 compounds, we performed pilot screens, against both MSI1 and MSI2, leading to the identification of 7 molecules for MSI1, 15 for MSI2 and 5 that inhibited both. A secondary FP dose-response screen validated 3 MSI inhibitors with IC50 below 10 μM. Out of the 25 compounds retested in the secondary screen only 8 demonstrated optical interference due to high fluorescence. Utilizing a SYBR-based RNA electrophoresis mobility shift assay (EMSA), we further verified MSI inhibition of the top 3 compounds. Surprisingly, even though several aminoglycosides were present in the library, they failed to demonstrate MSI inhibitor activity challenging the concept that these compounds are pan-active against RBPs. In summary, we have developed an in vitro strategy to identify MSI specific inhibitors using an FP HTS platform, which will facilitate novel drug discovery for this class of RBPs.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Michael G Kharas
- (Michael G. Kharas) Molecular Pharmacology & Chemistry Program, MSKCC, New York, USA.
| |
Collapse
|
35
|
Abstract
![]()
SETD8/SET8/Pr-SET7/KMT5A
is the sole protein lysine methyltransferase
(PKMT) known to monomethylate lysine 20 of histone H4 in vivo. SETD8’s methyltransferase activity has been implicated in
many essential cellular processes including DNA replication, DNA damage
response, transcription modulation, and cell cycle regulation. Developing
SETD8 inhibitors with cellular activity is a key step toward elucidating
the diverse roles of SETD8 via convenient pharmacological perturbation.
From the hits of a prior high throughput screen (HTS), SPS8I1–3 (NSC663284, BVT948, and ryuvidine) were validated as potent SETD8
inhibitors. These compounds contain different structural motifs and
inhibit SETD8 via distinct modes. More importantly, these compounds
show cellular activity by suppressing the H4K20me1 mark of SETD8 and
recapitulate characteristic S/G2/M-phase cell cycle defects as observed
for RNAi-mediated SETD8 knockdown. The commonality of SPS8I1–3 against SETD8, together with their distinct structures and mechanisms
for SETD8 inhibition, argues for the collective application of these
compounds as SETD8 inhibitors.
Collapse
Affiliation(s)
| | | | - Xiangjun Rao
- Department
of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, California 90089, United States
| | | | | | | | - Judd C. Rice
- Department
of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, California 90089, United States
| | | |
Collapse
|
36
|
Chau DM, Shum D, Radu C, Bhinder B, Gin D, Gilchrist ML, Djaballah H, Li YM. A novel high throughput 1536-well Notch1 γ -secretase AlphaLISA assay. Comb Chem High Throughput Screen 2014; 16:415-24. [PMID: 23448293 DOI: 10.2174/1386207311316060001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 01/24/2013] [Accepted: 02/03/2013] [Indexed: 11/22/2022]
Abstract
The Notch pathway plays a crucial role in cell fate decisions through controlling various cellular processes. Overactive Notch signal contributes to cancer development from leukemias to solid tumors. γ-Secretase is an intramembrane protease responsible for the final proteolytic step of Notch that releases the membrane-tethered Notch fragment for signaling. Therefore, γ-secretase is an attractive drug target in treating Notch-mediated cancers. However, the absence of high throughput γ-secretase assay using Notch substrate has limited the identification and development of γ- secretase inhibitors that specifically target the Notch signaling pathway. Here, we report on the development of a 1536- well γ-secretase assay using a biotinylated recombinant Notch1 substrate. We effectively assimilated and miniaturized this newly developed Notch1 substrate with the AlphaLISA detection technology and demonstrated its robustness with a calculated Z' score of 0.66. We further validated this optimized assay by performing a pilot screening against a chemical library consisting of ~5,600 chemicals and identified known γ-secretase inhibitors e.g. DAPT, and Calpeptin; as well as a novel γ-secretase inhibitor referred to as KD-I-085. This assay is the first reported 1536-well AlphaLISA format and represents a novel high throughput Notch1-γ-secretase assay, which provides an unprecedented opportunity to discover Notch-selective γ-secretase inhibitors that can be potentially used for the treatment of cancer and other human disorders.
Collapse
Affiliation(s)
- De-Ming Chau
- Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Bhinder B, Antczak C, Shum D, Radu C, Mahida JP, Liu-Sullivan N, Ibanez G, Raja BS, Calder PA, Djaballah H. Chemical & RNAi screening at MSKCC: a collaborative platform to discover & repurpose drugs to fight disease. Comb Chem High Throughput Screen 2014; 17:298-318. [PMID: 24661215 DOI: 10.2174/1386207317666140323132222] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2013] [Revised: 10/22/2013] [Accepted: 10/23/2013] [Indexed: 11/22/2022]
Abstract
Memorial Sloan Kettering Cancer Center (MSKCC) has implemented the creation of a full service state-of-the-art High-throughput Screening Core Facility (HTSCF) equipped with modern robotics and custom-built screening data management resources to rapidly store and query chemical and RNAi screening data outputs. The mission of the facility is to provide oncology clinicians and researchers alike with access to cost-effective HTS solutions for both chemical and RNAi screening, with an ultimate goal of novel target identification and drug discovery. HTSCF was established in 2003 to support the institution's commitment to growth in molecular pharmacology and in the realm of therapeutic agents to fight chronic diseases such as cancer. This endeavor required broad range of expertise in technology development to establish robust and innovative assays, large collections of diverse chemical and RNAi duplexes to probe specific cellular events, sophisticated compound and data handling capabilities, and a profound knowledge in assay development, hit validation, and characterization. Our goal has been to strive for constant innovation, and we strongly believe in shifting the paradigm from traditional drug discovery towards translational research now, making allowance for unmet clinical needs in patients. Our efforts towards repurposing FDA-approved drugs fructified when digoxin, identified through primary HTS, was administered in the clinic for treatment of stage Vb retinoblastoma. In summary, the overall aim of our facility is to identify novel chemical probes, to study cellular processes relevant to investigator's research interest in chemical biology and functional genomics, and to be instrumental in accelerating the process of drug discovery in academia.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Hakim Djaballah
- HTS Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
| |
Collapse
|
38
|
Bugiardini R, Badimon L, Manfrini O, Boytsov S, Bozidarka K, Daullxhiu I, Dilic M, Dorobantu M, Erglis A, Gafarov V, Gale CP, Goncalvesova E, Goudev A, Gustiene O, Hall A, Karpova I, Kedev S, Manak N, Milicic D, Ostojic M, Parkhomenko AN, Popovici M, Studenkan M, Toth K, Trninic D, Vasiljevic Z, Zakke I, Zaliunas R, Bugiardini R, Vaccarino V, Manfrini O, Badimon L, Manak N, Karpova I, Dilic M, Trninic D, Goudev A, Milicic D, Toth K, Daullxhiu I, Erglis A, Zakke I, Zaliunas R, Gustiene O, Kedev S, Popovici M, Knezevic B, Boytsov S, Gafarov V, Dorubantu M, Vasiljevic Z, Ojstoic M, Goncalvesova E, Studencan M, Parkhomenko AN, Hall A, Gale C, Karpova I, Manak N, Lovric M, Korac R, Mandic D, Vujovic V, Blagojevic M, Milekic J, Trendafilova E, Somleva D, Krivokapic L, Rajovic G, Sahmanovic O, Saranovic M, Radoman C, Tomic SC, Ljubic V, Velickovic M, Radojicic S, Arsenescu-Georfescu C, Garbea S, Radu C, Olinic D, Calin P, Chifor A, Babes K, lonescu DD, Craiu E, Petrescu H, Magda I, Luminita S, Benedek I, Marinescu S, Tiberiu N, Gheorghe G, Malaescu I, Trocan N, Doina D, Macarie C, Putnikovic B, Arandjelovic A, Nikolic NM, Zdravkovic M, Saric J, Radovanovic S, Matic I, Srbljak N, Davidovic G, Simovic S, Zivkovic S, Petkovic-Curic S, Studencan M, Parkhomenko AN. Perspectives: Rationale and design of the ISACS-TC (International Survey of Acute Coronary Syndromes in Transitional Countries) project. Eur Heart J Suppl 2014. [DOI: 10.1093/eurheartj/sut002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
39
|
Shum D, Bhinder B, Radu C, Farazi T, Landthaler M, Tuschl T, Calder P, Ramirez CN, Djaballah H. An image-based biosensor assay strategy to screen for modulators of the microRNA 21 biogenesis pathway. Comb Chem High Throughput Screen 2013; 15:529-41. [PMID: 22540737 DOI: 10.2174/138620712801619131] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2012] [Revised: 04/12/2011] [Accepted: 04/13/2012] [Indexed: 12/21/2022]
Abstract
microRNAs (miRNAs) are evolutionary conserved, small endogenous non-coding, RNA molecules. Although their mode of action has been extensively studied, little is known about their biogenesis. As their altered expression has been implicated in many diseases, small molecules that would modulate their expression are sought after. They are generated through the concerted action of several complexes which promote their transcription, maturation, export, trafficking, and loading of mature miRNA into silencing complexes. An increasing number of studies have suggested that each of these steps serves as a regulatory junction in the process, and therefore provides an intervention point. For this purpose, we have developed a simple image-based assay strategy to screen for such modulators. Here, we describe its successful implementation which combines the use of a microRNA 21 (miR-21) synthetic mimic together with an EGFP based reporter cell line, where its expression is under the control of miR-21, to monitor EGFP expression in a format suitable for HTS. The strategy was further validated using a small panel of known gene modulators of the miRNA pathway. A screen was performed in duplicate against a library of 6,912 compounds and identified 48 initial positives exhibiting enhanced EGFP fluorescence intensity. 42 compounds were found to be inherently fluorescent in the green channel leaving the remaining 6 as potential inhibitors and with a positive rate of 0.09%. Taken together, this validated strategy offers the opportunity to discover novel and specific inhibitors of the pathway through the screening of diverse chemical libraries.
Collapse
Affiliation(s)
- David Shum
- HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Antczak C, Wee B, Radu C, Bhinder B, Holland EC, Djaballah H. A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells. Assay Drug Dev Technol 2013; 12:28-42. [PMID: 23992118 DOI: 10.1089/adt.2013.521] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
ABCG2 is a member of the ATP-binding cassette (ABC) family of transporters, the overexpression of which has been implicated in resistance to various chemotherapeutic agents. Though a number of cell-based assays to screen for inhibitors have been reported, they do not provide a content-rich platform to discriminate toxic and autofluorescent compounds. To fill this gap, we developed a live high-content cell-based assay to identify inhibitors of ABCG2-mediated transport and, at the same time, assess their cytotoxic effect and potential optical interference. We used a pair of isogenic U87MG human glioblastoma cell lines, with one stably overexpressing the ABCG2 transporter. JC-1 (J-aggregate-forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazol carbocyanine iodide) was selected as the optimal reporter substrate for ABCG2 activity, and the resulting assay was characterized by a Z' value of 0.50 and a signal-to-noise (S/N) ratio of 14 in a pilot screen of ∼ 7,000 diverse chemicals. The screen led to the identification of 64 unique nontoxic positives, yielding an initial hit rate of 1%, with 58 of them being confirmed activity. In addition, treatment with two selected confirmed positives suppressed the side population of U87MG-ABCG2 cells that was able to efflux the Hoechst dye as measured by flow cytometry, confirming that they constitute potent new ABCG2 transporter inhibitors. Our results demonstrate that our live cell and content-rich platform enables the rapid identification and profiling of ABCG2 modulators, and this new strategy opens the door to the discovery of compounds targeting the expression and/or trafficking of ABC transporters as an alternative to functional inhibitors that failed in the clinic.
Collapse
Affiliation(s)
- Christophe Antczak
- 1 High-Throughput Screening Core Facility, Memorial Sloan-Kettering Cancer Center , New York, New York
| | | | | | | | | | | |
Collapse
|
41
|
Capilna B, Radu C. The association of month of birth with allergic sensitization in pediatric patients with asthma in Mureş County, Romania. Clin Transl Allergy 2013. [PMCID: PMC3723735 DOI: 10.1186/2045-7022-3-s3-p165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
42
|
Spiezia L, Visentin S, Radu C, Bon M, Woodhams B, Cosmi E, Simioni P. P-036 Changes in plasma levels of factor VIIa-antithrombin complex during normal pregnancy and in pre-eclampsia. Thromb Res 2013. [DOI: 10.1016/s0049-3848(13)70082-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Bhinder B, Antczak C, Ramirez CN, Shum D, Liu-Sullivan N, Radu C, Frattini MG, Djaballah H. An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates. Assay Drug Dev Technol 2012. [PMID: 23198867 DOI: 10.1089/adt.2012.475] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
RNA interference technology is becoming an integral tool for target discovery and validation.; With perhaps the exception of only few studies published using arrayed short hairpin RNA (shRNA) libraries, most of the reports have been either against pooled siRNA or shRNA, or arrayed siRNA libraries. For this purpose, we have developed a workflow and performed an arrayed genome-scale shRNA lethality screen against the TRC1 library in HeLa cells. The resulting targets would be a valuable resource of candidates toward a better understanding of cellular homeostasis. Using a high-stringency hit nomination method encompassing criteria of at least three active hairpins per gene and filtered for potential off-target effects (OTEs), referred to as the Bhinder-Djaballah analysis method, we identified 1,252 lethal and 6 rescuer gene candidates, knockdown of which resulted in severe cell death or enhanced growth, respectively. Cross referencing individual hairpins with the TRC1 validated clone database, 239 of the 1,252 candidates were deemed independently validated with at least three validated clones. Through our systematic OTE analysis, we have identified 31 microRNAs (miRNAs) in lethal and 2 in rescuer genes; all having a seed heptamer mimic in the corresponding shRNA hairpins and likely cause of the OTE observed in our screen, perhaps unraveling a previously unknown plausible essentiality of these miRNAs in cellular viability. Taken together, we report on a methodology for performing large-scale arrayed shRNA screens, a comprehensive analysis method to nominate high-confidence hits, and a performance assessment of the TRC1 library highlighting the intracellular inefficiencies of shRNA processing in general.
Collapse
Affiliation(s)
- Bhavneet Bhinder
- High-Throughput Screening Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi IY, Mukherjee-Clavin B, Djaballah H, Studer L. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 2012; 30:1244-8. [PMID: 23159879 PMCID: PMC3711177 DOI: 10.1038/nbt.2435] [Citation(s) in RCA: 172] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2012] [Accepted: 10/30/2012] [Indexed: 01/12/2023]
Abstract
Patient-specific induced pluripotent stem cells (iPSCs) represent a novel system for modeling human genetic disease and could develop into a key drug discovery platform. We recently reported disease-specific phenotypes in iPSCs from familial dysautonomia (FD) patients. FD is a rare but fatal genetic disorder affecting neural crest lineages. Here we demonstrate the feasibility of performing a primary screen in FD-iPSC derived neural crest precursors. Out of 6,912 compounds tested we characterized 8 hits that rescue expression of IKBKAP, the gene responsible for FD. One of those hits, SKF-86466, is shown to induce IKBKAP transcription via modulation of intracellular cAMP levels and PKA dependent CREB phosphorylation. SKF-86466 also rescues IKAP protein expression and the disease-specific loss of autonomic neuron marker expression. Our data implicate alpha-2 adrenergic receptor activity in regulating IKBKAP expression and demonstrate that small molecule discovery in an iPSC-based disease model can identify candidate drugs for potential therapeutic intervention.
Collapse
Affiliation(s)
- Gabsang Lee
- Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Research, New York, New York, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Shum D, Bhinder B, Ramirez CN, Radu C, Calder PA, Beauchamp L, Farazi T, Landthaler M, Tuschi T, Magdaleno S, Djaballah H. An arrayed RNA interference genome-wide screen identifies candidate genes involved in the MicroRNA 21 biogenesis pathway. Assay Drug Dev Technol 2012; 11:191-205. [PMID: 23153064 DOI: 10.1089/adt.2012.477] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
MicroRNAs (miRNAs) are evolutionary conserved noncoding molecules that regulate gene expression. They influence a number of diverse biological functions, such as development and differentiation. However, their dysregulation has been shown to be associated with disease states, such as cancer. Genes and pathways regulating their biogenesis remain unknown and are highly sought after. For this purpose, we have validated a multiplexed high-content assay strategy to screen for such modulators. Here, we describe its implementation that makes use of a cell-based gain-of-function reporter assay monitoring enhanced green fluorescent protein expression under the control of miRNA 21 (miR-21); combined with measures of both cell metabolic activities through the use of Alamar Blue and cell death through imaged Hoechst-stained nuclei. The strategy was validated using a panel of known genes and enabled us to successfully progress to and complete an arrayed genome-wide short interfering RNA (siRNA) screen against the Ambion Silencer Select v4.0 library containing 64,755 siRNA duplexes covering 21,565 genes. We applied a high-stringency hit analysis method, referred to as the Bhinder-Djaballah analysis method, leading to the nomination of 1,273 genes as candidate inhibitors of the miR-21 biogenesis pathway; after several iterations eliminating those genes with only one active duplex and those enriched in seed sequence mediated off-target effects. Biological classifications revealed four major control junctions among them vesicular transport via clathrin-mediated endocytosis. Altogether, our screen has uncovered a number of novel candidate regulators that are potentially good druggable targets allowing for the discovery and development of small molecules for regulating miRNA function.
Collapse
Affiliation(s)
- David Shum
- High-Throughput Screening Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, Sartori MT, Simioni P. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10:1823-9. [PMID: 22712870 DOI: 10.1111/j.1538-7836.2012.04824.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
INTRODUCTION Cirrhotic patients may present thrombotic complications that warrant anticoagulant therapy. However, the efficacy of low-molecular-weight heparin (LMWH) in this clinical setting is still unclear. AIMS/METHODS To evaluate the in vitro effect of LMWH on thrombin generation (TG) in cirrhotic patients at different stages of liver disease. Thirty cirrhotics (10 Child Pugh A, 10 Child Pugh B and 10 Child Pugh C), 10 subjects with inherited type 1 antithrombin (AT) defect and 10 healthy controls were studied. TG was determined at baseline and with anti-Xa levels after the addition of enoxaparin at 0.35 and 0.7 U anti-Xa mL. The endogenous thrombin potential (ETP) ratio at 0.35 and 0.7 U anti-Xa mL was obtained by dividing ETP with LMWH by ETP at baseline. RESULTS Mean AT levels in all cirrhotic subgroups and in patients with AT deficiency were significantly lower than in controls. The 0.35 ETP ratio was significantly lower in cirrhotic patients than in controls (0.26 ± 0.1 vs. 0.48 ± 0.1, P < 0.001) and the reduction paralleled the severity of liver disease, in spite of the concomitant decrease in AT and anti-Xa activity. AT-deficient subjects showed a significantly increased 0.35 ETP ratio compared with both cirrhotic patients and controls (0.69 ± 1 vs. 0.26 ± 0.1, P < 0.001, and vs. 0.48 ± 0.1, P = 0.04 respectively). LMWH at 0.7 U anti-Xa mL completely inhibited TG in 9/30 cirrhosis patients with more advanced liver disease (Child Pugh B and C), whereas complete TG abolition was seen in only 1/10 controls. CONCLUSIONS Cirrhotic patients show an increased response to LMWH, which correlates with the severity of liver disease, in spite of reduced AT and anti-Xa activity levels. Thrombin generation may be a useful tool to monitor the response to LMWH in cirrhotic patients.
Collapse
Affiliation(s)
- M Senzolo
- Multivisceral Transplant Unit, Department of Surgical and Gastroenterological Sciences. Padua University Hospital, Padua, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. J Physiol Pharmacol 2012; 63:347-353. [PMID: 23070083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/26/2012] [Accepted: 07/17/2012] [Indexed: 06/01/2023]
Abstract
Non-invasive biochemical markers are useful to distinguish between nonalcoholic steatohepatitis (NASH) and simple steatosis. The aim of this study was to test the diagnostic value of a panel of biomarkers derived from the pathophysiological events involved in the development of NASH. A total of 79 patients: 20 not-NASH and 59 NASH were included in the study. Definitive NASH was defined according to Kleiner's classification. In all subjects, parameters of the metabolic syndrome, insulin resistance (HOMA-IR), adiponectin, interleukin-6 (IL-6) and total cytokeratin-18 (M65 antigen) were determined. Univariate and multivariate analysis were used to identify independent predictors of NASH. In multivariate analysis three markers were independently predictors of NASH: adiponectin, IL-6 and M65 levels. In decreasing order, the independent predictors of NASH (NAS≥5) were M65 with an AUROC of 0.791, IL-6 with an AUROC of 0.727 and adiponectin with an AUROC of 0.709. The combination of two biomarkers yelded an AUROC of 0.828 for M65 and IL-6, 0.841 for adiponectin and M65 and 0.852 for adiponectin and IL-6. The best value was obtained by triple combination: adiponectin, M65 and IL-6 with and AUROC of 0.903, Sp=85.7% (PPV=94.2%) and Se=84.5% (NPV=66.7%). In conclusion, a novel pathophysiological - based panel of biomarkers combining total CK-18, IL-6 and adiponectin may be useful to predict NASH.
Collapse
Affiliation(s)
- M Grigorescu
- Regional Institute of Gastroenterology and Hepatology, 3rd Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
| | | | | | | | | | | |
Collapse
|
48
|
Radu C, Adrar HS, Alamir A, Hatherley I, Trinh T, Djaballah H. Designs and concept reliance of a fully automated high-content screening platform. ACTA ACUST UNITED AC 2012; 17:359-69. [PMID: 22797489 DOI: 10.1177/2211068212453311] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
High-content screening (HCS) is becoming an accepted platform in academic and industry screening labs and does require slightly different logistics for execution. To automate our stand-alone HCS microscopes, namely, an alpha IN Cell Analyzer 3000 (INCA3000), originally a Praelux unit hooked to a Hudson Plate Crane with a maximum capacity of 50 plates per run, and the IN Cell Analyzer 2000 (INCA2000), in which up to 320 plates could be fed per run using the Thermo Fisher Scientific Orbitor, we opted for a 4 m linear track system harboring both microscopes, plate washer, bulk dispensers, and a high-capacity incubator allowing us to perform both live and fixed cell-based assays while accessing both microscopes on deck. Considerations in design were given to the integration of the alpha INCA3000, a new gripper concept to access the onboard nest, and peripheral locations on deck to ensure a self-reliant system capable of achieving higher throughput. The resulting system, referred to as Hestia, has been fully operational since the new year, has an onboard capacity of 504 plates, and harbors the only fully automated alpha INCA3000 unit in the world.
Collapse
Affiliation(s)
- Constantin Radu
- Memorial Sloan-Kettering Cancer Center, New York, New York, USA
| | | | | | | | | | | |
Collapse
|
49
|
Takagi T, Shum D, Parisi M, Santos RE, Radu C, Calder P, Rizvi Z, Frattini MG, Djaballah H. Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase. Comb Chem High Throughput Screen 2012; 14:669-87. [PMID: 21564015 DOI: 10.2174/138620711796504442] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2010] [Revised: 03/19/2011] [Accepted: 04/26/2011] [Indexed: 12/20/2022]
Abstract
Several assay technologies have been successfully adapted and used in HTS to screen for protein kinase inhibitors; however, emerging comparative analysis studies report very low hit overlap between the different technologies, which challenges the working assumption that hit identification is not dependent on the assay method of choice. To help address this issue, we performed two screens on the cancer target, Cdc7-Dbf4 heterodimeric protein kinase, using a direct assay detection method measuring [(33)P]-phosphate incorporation into the substrate and an indirect method measuring residual ADP production using luminescence. We conducted the two screens under similar conditions, where in one, we measured [(33)P]-phosphate incorporation using scintillation proximity assay (SPA), and in the other, we detected luminescence signal of the ATP-dependent luciferase after regenerating ATP from residual ADP (LUM). Surprisingly, little or no correlation were observed between the positives identified by the two methods; at a threshold of 30% inhibition, 25 positives were identified in the LUM screen whereas the SPA screen only identified two positives, Tannic acid and Gentian violet, with Tannic acid being common to both. We tested 20 out of the 25 positive compounds in secondary confirmatory study and confirmed 12 compounds including Tannic acid as Cdc7-Dbf4 kinase inhibitors. Gentian violet, which was only positive in the SPA screen, inhibited luminescence detection and categorized as a false positive. This report demonstrates the strong impact in detection format on the success of a screening campaign and the importance of carefully designed confirmatory assays to eliminate those compounds that target the detection part of the assay.
Collapse
Affiliation(s)
- Toshimitsu Takagi
- HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ibanez G, Shum D, Blum G, Bhinder B, Radu C, Antczak C, Luo M, Djaballah H. A High Throughput Scintillation Proximity Imaging Assay for Protein Methyltransferases. Comb Chem High Throughput Screen 2012; 15:359-71. [DOI: 10.2174/138620712800194468] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2011] [Revised: 01/05/2012] [Accepted: 01/05/2012] [Indexed: 11/22/2022]
|